{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:41:19Z","timestamp":1783467679816,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Cooperative Study Program from the United States","award":["CSP 594"],"award-info":[{"award-number":["CSP 594"]}]}],"content-domain":{"domain":["contemporaryclinicaltrials.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.cct.2018.03.015","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T03:59:41Z","timestamp":1522123181000},"page":"102-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Design and Rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d Trial"],"prefix":"10.1016","volume":"68","author":[{"given":"S.","family":"Timilsina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Brittan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"O'Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Davis-Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Henrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Neogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Palevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pittman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.H.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.R.","family":"Mikuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.cct.2018.03.015_bb0005","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the national health and nutrition examination survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.cct.2018.03.015_bb0010","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/acr.21837","article-title":"Gout-related health care utilization in US emergency departments, 2006 through 2008","volume":"65","author":"Garg","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"4","key":"10.1016\/j.cct.2018.03.015_bb0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","article-title":"The impact of gout on work absence and productivity","volume":"10","author":"Kleinman","year":"2007","journal-title":"Value Health"},{"issue":"23","key":"10.1016\/j.cct.2018.03.015_bb0020","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2018.03.015_bb0025","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.cct.2018.03.015_bb0030","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.cct.2018.03.015_bb0035","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 american college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.cct.2018.03.015_bb0040","unstructured":"US Department of Veterans Affairs. Office of Research & Development. Cooperative studies program. https:\/\/www.research.va.gov\/programs\/csp\/. (Updated 2016). Accessed September 15, 2017)."},{"key":"10.1016\/j.cct.2018.03.015_bb0045","unstructured":"O'Dell JR. Nebraska medicine. Early Diagnosis Combined With New Treatments for Rheumatoid Arthritis Contribute to Significant Advances in Disease Control. https:\/\/www.nebraskamed.com\/for-providers\/early-diagnosis-combined-with-new-treatments-for-rheumatoid-arthritis-contribute-to-significant-advances-in-disease-control. (Updated 2017). Accessed September 15, 2017."},{"issue":"4","key":"10.1016\/j.cct.2018.03.015_bb0050","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1303006","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"O'Dell","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2018.03.015_bb0055","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). ICH harmonised guideline. Integrated addendum to ICH E6(R1):Guideline for good clinical practice E6(R2). http:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/integrated-addendum-good-clinical-practice.html. (Updated 2016). Accessed September 15, 2017."},{"issue":"3","key":"10.1016\/j.cct.2018.03.015_bb0060","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3899\/jrheum.140588","article-title":"Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system","volume":"42","author":"Rashid","year":"2015","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.cct.2018.03.015_bb0065","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.cct.2018.03.015_bb0070","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.cct.2018.03.015_bb0075","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","article-title":"Developing a provisional definition of flare in patients with established gout","volume":"64","author":"Gaffo","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.cct.2018.03.015_bb0080","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1007\/s00296-015-3284-3","article-title":"Patient and clinical characteristics associated with gout flares in an integrated healthcare system","volume":"35","author":"Rashid","year":"2015","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.cct.2018.03.015_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.1780290111","article-title":"The allopurinol hypersensitivity syndrome. Unnecessary morbidity and mortality","volume":"29","author":"Singer","year":"1986","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.cct.2018.03.015_bb0095","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/RHU.0b013e31829372e6","article-title":"Association between adverse reactions to allopurinol and exposures to high maintenance doses: implications for management of patients using allopurinol","volume":"19","author":"Paisansinsup","year":"2013","journal-title":"J. Clin. Rheumatol."},{"issue":"5","key":"10.1016\/j.cct.2018.03.015_bb0100","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.semarthrit.2016.10.009","article-title":"The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States","volume":"46","author":"Jutkowitz","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cct.2018.03.015_bb0105","series-title":"Statistical Analysis with Missing Data","author":"Little","year":"2002"},{"key":"10.1016\/j.cct.2018.03.015_bb0110","series-title":"Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis","author":"Daniels","year":"2008"},{"issue":"Suppl. 2","key":"10.1016\/j.cct.2018.03.015_bb0115","first-page":"ii9","article-title":"Treating to target: a strategy to cure gout","volume":"48","author":"Perez-Ruiz","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.cct.2018.03.015_bb0120","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","article-title":"Allopurinol dose escalation to achieve serum urate below 6\u202fmg\/dL: an open-label extension study","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.cct.2018.03.015_bb0125","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/MJT.0b013e318250f83d","article-title":"Management of gouty arthritis in patients with chronic kidney disease","volume":"21","author":"Abdellatif","year":"2014","journal-title":"Am. J. Ther."},{"issue":"9","key":"10.1016\/j.cct.2018.03.015_bb0130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.cct.2018.03.015_bb0135","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.cct.2018.03.015_bb0140","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2017-211210","article-title":"Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of medicare claims data","volume":"76","author":"Singh","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cct.2018.03.015_bb0150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11926-009-0019-z","article-title":"A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout","volume":"11","author":"Chao","year":"2009","journal-title":"Curr. Rheumatol. Rep."},{"issue":"8\u20139","key":"10.1016\/j.cct.2018.03.015_bb0155","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1081\/NCN-200027377","article-title":"PK\/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment","volume":"23","author":"Hoshide","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am. J. Ther."},{"issue":"8","key":"10.1016\/j.cct.2018.03.015_bb0165","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cct.2018.03.015_bb0170","first-page":"128","article-title":"Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients","volume":"4","author":"Momeni","year":"2010","journal-title":"Iran. J. Kidney Dis."},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout: long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J. Clin. Rheumatol."},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3810\/pgm.2013.01.2626","article-title":"Preservation of renal function during gout treatment with febuxostat: a quantitative study","volume":"125","author":"Whelton","year":"2013","journal-title":"Postgrad. Med."},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.cct.2018.03.015_bb0190","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin. Dial."},{"issue":"5","key":"10.1016\/j.cct.2018.03.015_bb0195","first-page":"384","article-title":"Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?","volume":"49","author":"Lee","year":"2008","journal-title":"Singap. Med. J."},{"issue":"2","key":"10.1016\/j.cct.2018.03.015_bb0200","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cct.2018.03.015_bb0205","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British society for rheumatology and british health professionals in rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.cct.2018.03.015_bb0210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann. Intern. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714417306869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714417306869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T23:19:16Z","timestamp":1528931956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714417306869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":42,"alternative-id":["S1551714417306869"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2018.03.015","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and Rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d Trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2018.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}